Natalizumab for Rapidly Evolving Severe Relapsing-Remitting Multiple Sclerosis (RESRRMS) Patients- 5-Year Budget Impact Analysis (BIA) from the Brazilian Public Payer Perspective
Abstract
Authors
A.M. Nishikawa L. Paladini A.L. Liamas C.C. Bueno O.A.C. Clark